Patents by Inventor Sanjib Das
Sanjib Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312486Abstract: The present invention is directed to solid state forms of a compound which has retinoid-related orphan receptor gamma (RORy) modulator activity. Particularly the present invention relates to solid state forms of the compound (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl) acetamide, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy. More, particularly the present invention relates to crystalline form of the compound (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl)acetamide, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.Type: ApplicationFiled: September 3, 2021Publication date: October 5, 2023Inventors: Sanjib DAS, Sachin Sundarlal CHAUDHARI, Laxmikant Atmaram GHARAT, Suresh Mahadev KADAM, Sachin GAVHANE, Bipin Parsottam KANSAGRA, Shailesh Shrirang PAWASE, Anil Subhash BHUJBAL, Ulhas Digambar PATIL, Sunil Pandurang NIRGUDE
-
Publication number: 20230285188Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat intraocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject’ eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.Type: ApplicationFiled: August 11, 2022Publication date: September 14, 2023Inventors: Tomas Navratil, Sanjib Das, Andres Garcia, Janet Tully
-
Publication number: 20230227483Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.Type: ApplicationFiled: July 6, 2022Publication date: July 20, 2023Inventors: Pravin IYER, Sanjib DAS, Murugan CHINNAPATTU, Sachin CHAUDHARI, Jagmohan SAINI, Sravan MANDADI, Nagaraj GOWDA, Dnyaneshwar DAHALE, Sandip PATIL, Nanasaheb KADLAG, Chandrasekhar MISRA, Priyanka PANGARE
-
Publication number: 20230094837Abstract: Embodiments relate to a crosslinked citrate-based elastomer catheter that is biodegradable and kink resistant. Embodiments of the crosslinked citrate-based elastomer material swells when surrounded by fluid (body fluid) so as to anchor the catheter to tissue but not anchor it so much that movement or removal will cause tissue damage. The catheter can be used as a component to a peripheral nerve block device, for example. Embodiments of the catheter can include embedding biodegradable sensors, moieties, shape memory material, etc. to monitor and modulate functions of the catheter and/or peripheral nerve block.Type: ApplicationFiled: April 7, 2021Publication date: March 30, 2023Inventors: Jian Yang, Ethan Gerhard, Yuqi Wang, Huanyu Cheng, Sanjib Das Adhikary
-
Publication number: 20210228408Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat ocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject' eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.Type: ApplicationFiled: July 25, 2016Publication date: July 29, 2021Inventors: Tomas Navratil, Sanjib Das, Andres Garcia, Janet Tully
-
Patent number: 10988467Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: GrantFiled: May 3, 2019Date of Patent: April 27, 2021Assignee: Glenmark Pharmaceuticals S.A.Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Publication number: 20190256508Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: ApplicationFiled: May 3, 2019Publication date: August 22, 2019Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Patent number: 10344024Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: GrantFiled: April 18, 2018Date of Patent: July 9, 2019Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Patent number: 10336688Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: GrantFiled: November 29, 2018Date of Patent: July 2, 2019Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Dnyaneshwar E. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Publication number: 20190144375Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: ApplicationFiled: November 29, 2018Publication date: May 16, 2019Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Dnyaneshwar E. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Patent number: 10189775Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: GrantFiled: August 26, 2016Date of Patent: January 29, 2019Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Dnyaneshwar E. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Publication number: 20180237428Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related Sorphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: ApplicationFiled: April 18, 2018Publication date: August 23, 2018Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Publication number: 20180237382Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: ApplicationFiled: August 26, 2016Publication date: August 23, 2018Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Dnyaneshwar E. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Patent number: 9975887Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: GrantFiled: August 2, 2016Date of Patent: May 22, 2018Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
-
Publication number: 20170233380Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.Type: ApplicationFiled: August 2, 2016Publication date: August 17, 2017Inventors: Sanjib DAS, Laxmikant A. GHARAT, Rajendra L. HARDE, Sandeep Y. SHELKE, Shailesh R. PARDESHI, Abraham THOMAS, Neelima KHAIRATKAR-JOSHI, Daisy M. SHAH, Malini BAJPAI
-
Patent number: 9682977Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X1, M, R2, R3, R4, R5, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer.Type: GrantFiled: December 9, 2014Date of Patent: June 20, 2017Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Sanjib Das, Sachin Sundarlal Chaudhari, Abraham Thomas, Shailesh Ramesh Pardeshi, Vishal Govindrao Deshmukh, Prashant Dilip Wadekar, Neelima Khairatkar-Joshi, Daisy Manish Shah, Malini Bajpai
-
Publication number: 20160326163Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X1, M, R2, R3, R4, R5, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer.Type: ApplicationFiled: December 9, 2014Publication date: November 10, 2016Inventors: Sanjib DAS, Sachin Sundarlal CHAUDHARI, Abraham THOMAS, Shailesh Ramesh PARDESHI, Vishal Govindrao DESHMUKH, Prashant Dilip WADEKAR, Neelima KHAIRATKAR-JOSHI, Daisy Manish SHAH, Malini BAJPAI
-
Publication number: 20150265777Abstract: A safety needle device includes a housing with a needle and stylet located therein. The needle includes an elongate needle portion with a distal tip. The stylet includes an elongate stylet portion with a distal tip. The safety needle device also includes a compression spring and a sliding member coupled to the needle. A method of navigating the safety needle device toward a point is also provided.Type: ApplicationFiled: March 17, 2015Publication date: September 24, 2015Inventors: Kenneth W. WHITLEY, Sanjib Das ADHIKARY
-
Patent number: 8178534Abstract: Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the compounds.Type: GrantFiled: August 14, 2009Date of Patent: May 15, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Jerome C. Bressi, Shaosong Chu, Philip Erickson, Mallareddy Komandla, Lily Kwok, John D Lawson, Jeffrey A Stafford, Michael B. Wallace, Zhiyuan Zhang, Sanjib Das
-
Publication number: 20100063054Abstract: Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: August 14, 2009Publication date: March 11, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jerome C. Bressi, Shaosong Chu, Philip Erickson, Mallareddy Komandla, Lily Kwok, John D. Lawson, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang, Sanjib Das